PMC:7321036 / 110114-110536 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T35","span":{"begin":82,"end":86},"obj":"Body_part"},{"id":"T36","span":{"begin":383,"end":387},"obj":"Body_part"}],"attributes":[{"id":"A35","pred":"fma_id","subj":"T35","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A36","pred":"fma_id","subj":"T36","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"In addition to the time-course experiment, we also estimated kinase activities of cell line perturbation in a range of biological conditions using the K-test based approach, from a large resource of previously published phosphoproteomics datasets comprising of 435 biological conditions which include several drug treatments (chlorzoxazone, paclitaxel), inhibitors (EGFRi, AKTi) and cell cycle states (Ochoa et al., 2016)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T74","span":{"begin":68,"end":78},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T75","span":{"begin":82,"end":91},"obj":"http://purl.obolibrary.org/obo/CLO_0000031"},{"id":"T76","span":{"begin":108,"end":109},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T77","span":{"begin":153,"end":157},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T78","span":{"begin":179,"end":180},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T79","span":{"begin":383,"end":387},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"In addition to the time-course experiment, we also estimated kinase activities of cell line perturbation in a range of biological conditions using the K-test based approach, from a large resource of previously published phosphoproteomics datasets comprising of 435 biological conditions which include several drug treatments (chlorzoxazone, paclitaxel), inhibitors (EGFRi, AKTi) and cell cycle states (Ochoa et al., 2016)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T31298","span":{"begin":309,"end":313},"obj":"Chemical"},{"id":"T55659","span":{"begin":326,"end":339},"obj":"Chemical"},{"id":"T66943","span":{"begin":341,"end":351},"obj":"Chemical"},{"id":"T86581","span":{"begin":354,"end":364},"obj":"Chemical"}],"attributes":[{"id":"A25429","pred":"chebi_id","subj":"T31298","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A34614","pred":"chebi_id","subj":"T55659","obj":"http://purl.obolibrary.org/obo/CHEBI_3655"},{"id":"A15743","pred":"chebi_id","subj":"T66943","obj":"http://purl.obolibrary.org/obo/CHEBI_45863"},{"id":"A99759","pred":"chebi_id","subj":"T86581","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"In addition to the time-course experiment, we also estimated kinase activities of cell line perturbation in a range of biological conditions using the K-test based approach, from a large resource of previously published phosphoproteomics datasets comprising of 435 biological conditions which include several drug treatments (chlorzoxazone, paclitaxel), inhibitors (EGFRi, AKTi) and cell cycle states (Ochoa et al., 2016)."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T25","span":{"begin":61,"end":78},"obj":"http://purl.obolibrary.org/obo/GO_0016301"},{"id":"T26","span":{"begin":383,"end":393},"obj":"http://purl.obolibrary.org/obo/GO_0007049"}],"text":"In addition to the time-course experiment, we also estimated kinase activities of cell line perturbation in a range of biological conditions using the K-test based approach, from a large resource of previously published phosphoproteomics datasets comprising of 435 biological conditions which include several drug treatments (chlorzoxazone, paclitaxel), inhibitors (EGFRi, AKTi) and cell cycle states (Ochoa et al., 2016)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2351","span":{"begin":326,"end":339},"obj":"Chemical"},{"id":"2352","span":{"begin":341,"end":351},"obj":"Chemical"}],"attributes":[{"id":"A2351","pred":"tao:has_database_id","subj":"2351","obj":"MESH:D002753"},{"id":"A2352","pred":"tao:has_database_id","subj":"2352","obj":"MESH:D017239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In addition to the time-course experiment, we also estimated kinase activities of cell line perturbation in a range of biological conditions using the K-test based approach, from a large resource of previously published phosphoproteomics datasets comprising of 435 biological conditions which include several drug treatments (chlorzoxazone, paclitaxel), inhibitors (EGFRi, AKTi) and cell cycle states (Ochoa et al., 2016)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T940","span":{"begin":0,"end":422},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In addition to the time-course experiment, we also estimated kinase activities of cell line perturbation in a range of biological conditions using the K-test based approach, from a large resource of previously published phosphoproteomics datasets comprising of 435 biological conditions which include several drug treatments (chlorzoxazone, paclitaxel), inhibitors (EGFRi, AKTi) and cell cycle states (Ochoa et al., 2016)."}

{"project":"2_test","denotations":[{"id":"32645325-27909043-20773121","span":{"begin":416,"end":420},"obj":"27909043"}],"text":"In addition to the time-course experiment, we also estimated kinase activities of cell line perturbation in a range of biological conditions using the K-test based approach, from a large resource of previously published phosphoproteomics datasets comprising of 435 biological conditions which include several drug treatments (chlorzoxazone, paclitaxel), inhibitors (EGFRi, AKTi) and cell cycle states (Ochoa et al., 2016)."}